摘要
目的 探讨碳酸锂与丙戊酸钠治疗精神分裂症伴攻击行为患者的临床疗效和安全性.方法 将78例精神分裂症伴攻击行为患者按随机数字表法分为两组,每组39例,均常规应用抗精神病药物治疗,碳酸锂组联合口服碳酸锂缓释片治疗,丙戊酸钠组联合口服丙戊酸钠片治疗,观察8周.采用阳性与阴性症状量表、修订后外显攻击行为量表评定临床疗效,副反应量表评定不良反应.结果 治疗前两组各量表评分比较差异无统计学意义（P〉0.05）,治疗第2周末起两组阳性与阴性症状量表、修订后外显攻击行为量表评分显著低于治疗前（P〈0.05或0.01）,碳酸锂组治疗第4周、8周末评分显著低于丙戊酸钠组（P〈0.01）;两组不良反应均为轻、中度,发生率比较差异均无统计学意义（P〉0.05）.结论 碳酸锂与丙戊酸钠治疗伴发攻击行为的精神分裂症患者疗效显著,安全性好,但碳酸锂疗效优于丙戊酸钠.
Objective To study the clinical efficacy and security of lithium carbonate and sodium valproate in the treatment of aggressive behavior in schizophreniac patients. Method Seventy-eight schizophreniac patients with aggressive behavior were included in this study, and were randomly divided into two groups （39 cases in each group）. During the 8-week treatment, except for the conventional antipsychotic drug, additional lithium carbonate（LC） and sodium valproate （SV） were applied in two groups, respectively. The clinical efficacy was evaluated with Positive And Negative Syndrome Scale （PANSS） and Modified Overt Aggression Scale （MOAS）, the side effect was assessed with Treatment Emergent Symptom Scale （TESS）. Result Before treatment, each scale was not significantly different in both groups （P〉0.05） ; after 2wks of treatment, the PANSS and MOAS scores in two groups significantly decreased （P〈0.05 or 0.01）; the scores in LC group after 4wks and 8wks of treatment were significantly lower than those in SV group （P〈0.01）; the adverse reactions in two groups were mild or moderate, and were not significantly different （P〈0.05）. Conclusion In the treatment of aggressive behavior in schizophreniac patients, LC and SV both have remarkable curative effect with high safety, in which LC is better than SV.
作者
郭玉花
张毓茂
黄河
施明南
杨邦才
Guo Yuhua Zhang Yumao Huang He Shi Mingnan Yang Bangcai(Nanping Ningkang Hospital, Nanping 353000, Fujian, Chin)
出处
《临床心身疾病杂志》
CAS
2017年第5期39-42,共4页
Journal of Clinical Psychosomatic Diseases
关键词
精神分裂症
攻击行为
碳酸锂
丙戊酸钠
抗精神病药物
心境稳定剂
Schizophrenia
aggressive behavior
lithium carbonate
sodium valproate
antipsychotics
mood stabilizer
